2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13A.01 Preliminary Efficacy and Safety of Adebrelimab Plus Famitinib as Later-line Treatment for Extensive-Stage Small Cell Lung Cancer: A Phase 2 Trial

EP.13A.01 Preliminary Efficacy and Safety of Adebrelimab Plus Famitinib as Later-line Treatment for Extensive-Stage Small Cell Lung Cancer: A Phase 2 Trial

Back to course

Pdf Summary

The document summarizes a Phase 2 clinical trial investigating the efficacy and safety of a combination therapy consisting of Adebrelimab, an anti-PD-L1 antibody, and Famitinib, a receptor tyrosine kinase inhibitor, for patients with extensive-stage small-cell lung cancer (ES-SCLC) who experienced failure or intolerance to second-line systemic chemotherapy. The trial included patients aged 18-80 with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.<br /><br />The trial employed Simon's two-stage design and included 13 participants. Efficacy findings indicated that the objective response rate (ORR) was 23.1%, with 3 out of 13 patients achieving partial response (PR). The disease control rate (DCR) was 69.2%, suggesting a significant portion of patients sustained disease stabilization. The median progression-free survival (PFS) reported was 4.0 months.<br /><br />Safety data noted treatment-related adverse events (TRAEs) in 84.6% of patients, with 23.1% experiencing Grade 3 adverse events. Common adverse reactions included decreased neutrophil and white blood cell counts, hyponatremia, increased blood bilirubin, and other conditions such as nausea and decreased appetite. <br /><br />Conclusions of the study highlight that the combination of Adebrelimab and Famitinib displayed promising antitumor efficacy with manageable toxicity for relapsed ES-SCLC. The encouraging outcomes suggest further exploration of this therapeutic approach is warranted.<br /><br />Overall, the trial provides initial data supporting the potential use of Adebrelimab plus Famitinib as a treatment for patients with advanced ES-SCLC, extending treatment options for individuals who have not responded to previous therapies.

Asset Subtitle

Yutao Liu

Meta Tag

Speaker Yutao Liu

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

Phase 2 clinical trial

Adebrelimab

Famitinib

extensive-stage small-cell lung cancer

anti-PD-L1 antibody

receptor tyrosine kinase inhibitor

objective response rate

disease control rate

treatment-related adverse events

progression-free survival